Skip to content
Screener

AnaptysBio, Inc. ANAB Operating Lease Liabilities

Operating Lease Liabilities at other companies

Biogen logo
BiogenBIIB
$264.8M-14.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$965K-17.5%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$129.95M-5.3%
Absci Corporation logo
Absci CorporationABSI
$2.15M-46.4%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$4.91M-37.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$0-100%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemMarch 31, 2026(unaudited)December 31, 2025
Current portion of operating lease liability2,1202,080
Total current liabilities41,70238,625
Liability related to sale of future royalties263,742276,528
Operating lease liability, net of current portion11,49312,032
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.001 par value, 500,000 shares authorized, 29,031 shares and 28,019 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively2928
Additional paid-in capital838,307809,765

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s operating lease liabilities?
AnaptysBio, Inc. (ANAB) reported operating lease liabilities of $11.49M in Q1 2026.
How has AnaptysBio, Inc.'s operating lease liabilities changed year-over-year?
AnaptysBio, Inc.'s operating lease liabilities decreased by 15.6% year-over-year, from $13.61M to $11.49M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about AnaptysBio, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude